Industry
Biotechnology
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 1:16 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 9:09 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 10:58 am
Portfolio Pulse from Avi Kapoor
June 17, 2024 | 5:21 pm
Portfolio Pulse from Avi Kapoor
June 13, 2024 | 6:07 pm
Portfolio Pulse from Benzinga Insights
June 13, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
June 11, 2024 | 1:39 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
June 07, 2024 | 7:05 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 6:26 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.